Generate Biomedicines, Inc.
A Massachusetts biotech company that uses machine learning to design entirely new protein-based medicines from scratch, rather than hunting for molecules that already exist in nature. Founded in 2018 inside Flagship Pioneering's incubator, it spent its first three years in stealth before publicly launching its platform in 2020. The name reflects the mission: where other firms "discover" drugs, this one *generates* them.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Flagship Pioneering, LLC | 13GPassive | 48.9% | 62.67M | May 15, 2026 |
| Afeyan Noubar | 13GPassive | 48.9% | 62.70M | May 15, 2026 |
| Flagship VentureLabs VI, LLC | 13GPassive | 19.5% | 25.02M | May 15, 2026 |
| Flagship VentureLabs VI Manager LLC | 13GPassive | 19.5% | 25.02M | May 15, 2026 |
| Flagship Pioneering Fund VII, L.P. | 13GPassive | 13.1% | 16.83M | May 15, 2026 |
| Flagship Pioneering Fund VII General Partner LLC | 13GPassive | 13.1% | 16.83M | May 15, 2026 |
| Flagship Pioneering Fund VI, L.P. | 13GPassive | 9.9% | 12.72M | May 15, 2026 |
| Flagship Pioneering Fund VI General Partner LLC | 13GPassive | 9.9% | 12.72M | May 15, 2026 |
| Nally Michael | 13GPassive | 5.2% | 6.92M | May 15, 2026 |
| FPN II, L.P. | 13GPassive | 3.4% | 4.34M | May 15, 2026 |